Last €21.50 EUR
Change Today +0.20 / 0.94%
Volume 0.0
As of 5:49 AM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s (LDB) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/21/14 - €23.39
52 Week Low
06/25/13 - €12.98
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for H LUNDBECK A/S (LDB)

Related News

No related news articles were found.

h lundbeck a/s (LDB) Related Businessweek News

View More BusinessWeek News

h lundbeck a/s (LDB) Details

H. Lundbeck A/S, a specialty pharmaceutical company, engages in the research, development, production, marketing, and sale of pharmaceuticals for the treatment of brain disorders in Europe, the United States, and internationally. The company’s principal products include Cipralex and Lexapro to treat depression, Ebixa for Alzheimer’s disease, Azilect to treat Parkinson’s disease, Xenazine for chorea associated with Huntington's disease, Sabril to treat epilepsy, Sycrest for bipolar disorder, and Onfi to treat Lennox-Gastaut syndrome. Its compounds in registration application include aripiprazole IM depot for the treatment of schizophrenia; Selincro for alcohol dependence; and Brintellix for the treatment of depression and anxiety. The company’s products in Phase III trials comprise IV carbamazepine for epilepsy; Brexpiprazole for psychiatric disorders; Desmoteplase for stroke; and Zicronapine for psychosis. Its products in Phase II trials include Tedatioxetine for depression and Lu AE58054 for Alzheimer's disease. H. Lundbeck A/S has strategic research collaboration with Ossianix, Inc. The company was founded in 1915 and is based in Valby, Denmark.

5,518 Employees
Last Reported Date: 02/6/14
Founded in 1915

h lundbeck a/s (LDB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s (LDB) Key Developments

Lundbeck Signs Partnership with Lieber Institute for Brain Development on Schizophrenia

Lundbeck announced on 31 March the signature of a collaboration agreement with Lieber Institute for Brain Development (LIBD). The aim of the partnership is to develop new treatments for schizophrenia patients. In particular, the partners are interested in studying how genes impact brain development and mental health disorders. The financial terms of the collaboration were not disclosed by the two partners.

H. Lundbeck A/S Presents at Exane 16th Annual Healthcare Conference, Mar-25-2014

H. Lundbeck A/S Presents at Exane 16th Annual Healthcare Conference, Mar-25-2014 . Venue: Paris, France.

H. Lundbeck A/S - Shareholder/Analyst Call

Annual General meeting


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LDB:GR €21.50 EUR +0.20

LDB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LDB.
View Industry Companies

Industry Analysis


Industry Average

Valuation LDB Industry Range
Price/Earnings 36.2x
Price/Sales 2.0x
Price/Book 2.3x
Price/Cash Flow 36.2x
TEV/Sales 1.5x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at